Scynexis Inc

NASDAQ:SCYX   3:59:42 PM EDT
4.98
-0.02 (-0.40%)
Products, Regulatory, Other Pre-Announcement

Scynexis Announces Submission Of New Drug Application To The U.S. Food And Drug Administration For Oral Ibrexafungerp

Published: 10/14/2020 12:50 GMT
SCYNEXIS Inc (SCYX) - Scynexis Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection.
Scynexis Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection.
Scynexis Inc - NDA Submission is Supported by Positive Data From Twophase 3 Studies(vanish Program)in Women With Vulvovaginal Candidiasis.
Scynexis Inc - Ibrexafungerp is Expected to Receive a 6-month Priority Review Following NDA Acceptance.
Scynexis Inc - Expects to Receive Notification If NDA Has Been Accepted for Filing and Substantive Review in December 2020.
Scynexis Inc - Under Qidp Designation, Ibrexafungerp is Eligible for an Additional Five Years of Market Exclusivity.